Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.
Identifieur interne : 001402 ( PubMed/Curation ); précédent : 001401; suivant : 001403Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.
Auteurs : Cordula A. Jilg ; Anja Leifert ; Daniel Schnell ; Simon Kirste ; Natalia Volegova-Neher ; Daniel Schlager ; Gesche Wieser ; Karl Henne ; Wolfgang Schultze-Seemann ; Anca-L Grosu ; Hans Christian Rischke [Allemagne]Source :
- Radiation oncology (London, England) [ 1748-717X ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Choline, Humains, Imagerie multimodale, Lymphadénectomie (), Mâle, Métastase lymphatique (imagerie diagnostique), Qualité de vie, Radio-isotopes du carbone, Radio-isotopes du fluor, Radiopharmaceutiques, Radiothérapie adjuvante (), Récidive tumorale locale (), Récidive tumorale locale (imagerie diagnostique), Récidive tumorale locale (radiothérapie), Sujet âgé, Tomodensitométrie, Tomographie par émission de positons, Tumeurs de la prostate (), Tumeurs de la prostate (imagerie diagnostique), Tumeurs de la prostate (radiothérapie).
- MESH :
- imagerie diagnostique : Métastase lymphatique, Récidive tumorale locale, Tumeurs de la prostate.
- radiothérapie : Récidive tumorale locale, Tumeurs de la prostate.
- Adulte d'âge moyen, Choline, Humains, Imagerie multimodale, Lymphadénectomie, Mâle, Qualité de vie, Radio-isotopes du carbone, Radio-isotopes du fluor, Radiopharmaceutiques, Radiothérapie adjuvante, Récidive tumorale locale, Sujet âgé, Tomodensitométrie, Tomographie par émission de positons, Tumeurs de la prostate.
English descriptors
- KwdEn :
- Aged, Carbon Radioisotopes, Choline, Fluorine Radioisotopes, Humans, Lymph Node Excision (methods), Lymphatic Metastasis (diagnostic imaging), Male, Middle Aged, Multimodal Imaging, Neoplasm Recurrence, Local (diagnostic imaging), Neoplasm Recurrence, Local (radiotherapy), Neoplasm Recurrence, Local (surgery), Positron-Emission Tomography, Prostatic Neoplasms (diagnostic imaging), Prostatic Neoplasms (radiotherapy), Prostatic Neoplasms (surgery), Quality of Life, Radiopharmaceuticals, Radiotherapy, Adjuvant (methods), Tomography, X-Ray Computed.
- MESH :
- chemical : Carbon Radioisotopes, Choline, Fluorine Radioisotopes, Radiopharmaceuticals.
- diagnostic imaging : Lymphatic Metastasis, Neoplasm Recurrence, Local, Prostatic Neoplasms.
- methods : Lymph Node Excision, Radiotherapy, Adjuvant.
- radiotherapy : Neoplasm Recurrence, Local, Prostatic Neoplasms.
- surgery : Neoplasm Recurrence, Local, Prostatic Neoplasms.
- Aged, Humans, Male, Middle Aged, Multimodal Imaging, Positron-Emission Tomography, Quality of Life, Tomography, X-Ray Computed.
Abstract
In a previous study we demonstrated that, based on 11C/18 F-choline positron emission tomography-computerized-tomography as a diagnostic tool, salvage lymph node dissection (LND) plus adjuvant radiotherapy (ART) is feasible for treatment of pelvic/retroperitoneal nodal recurrence of prostate cancer (PCa). However, the toxicity of this combined treatment strategy has not been systematically investigated before. The aim of the current study was to evaluate the acute and late toxicity and quality of life of ART after LND in pelvic/retroperitoneal nodal recurrent PCa.
DOI: 10.1186/1748-717X-9-178
PubMed: 25112785
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001402
Links to Exploration step
pubmed:25112785Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.</title><author><name sortKey="Jilg, Cordula A" sort="Jilg, Cordula A" uniqKey="Jilg C" first="Cordula A" last="Jilg">Cordula A. Jilg</name></author><author><name sortKey="Leifert, Anja" sort="Leifert, Anja" uniqKey="Leifert A" first="Anja" last="Leifert">Anja Leifert</name></author><author><name sortKey="Schnell, Daniel" sort="Schnell, Daniel" uniqKey="Schnell D" first="Daniel" last="Schnell">Daniel Schnell</name></author><author><name sortKey="Kirste, Simon" sort="Kirste, Simon" uniqKey="Kirste S" first="Simon" last="Kirste">Simon Kirste</name></author><author><name sortKey="Volegova Neher, Natalia" sort="Volegova Neher, Natalia" uniqKey="Volegova Neher N" first="Natalia" last="Volegova-Neher">Natalia Volegova-Neher</name></author><author><name sortKey="Schlager, Daniel" sort="Schlager, Daniel" uniqKey="Schlager D" first="Daniel" last="Schlager">Daniel Schlager</name></author><author><name sortKey="Wieser, Gesche" sort="Wieser, Gesche" uniqKey="Wieser G" first="Gesche" last="Wieser">Gesche Wieser</name></author><author><name sortKey="Henne, Karl" sort="Henne, Karl" uniqKey="Henne K" first="Karl" last="Henne">Karl Henne</name></author><author><name sortKey="Schultze Seemann, Wolfgang" sort="Schultze Seemann, Wolfgang" uniqKey="Schultze Seemann W" first="Wolfgang" last="Schultze-Seemann">Wolfgang Schultze-Seemann</name></author><author><name sortKey="Grosu, Anca L" sort="Grosu, Anca L" uniqKey="Grosu A" first="Anca-L" last="Grosu">Anca-L Grosu</name></author><author><name sortKey="Rischke, Hans Christian" sort="Rischke, Hans Christian" uniqKey="Rischke H" first="Hans Christian" last="Rischke">Hans Christian Rischke</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Albert-Ludwigs University of Freiburg, Robert-Koch-Str, 3, 79106 Freiburg, Germany. hans.christian.rischke@uniklinik-freiburg.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Radiation Oncology, Albert-Ludwigs University of Freiburg, Robert-Koch-Str, 3, 79106 Freiburg</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25112785</idno><idno type="pmid">25112785</idno><idno type="doi">10.1186/1748-717X-9-178</idno><idno type="wicri:Area/PubMed/Corpus">001402</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001402</idno><idno type="wicri:Area/PubMed/Curation">001402</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001402</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.</title><author><name sortKey="Jilg, Cordula A" sort="Jilg, Cordula A" uniqKey="Jilg C" first="Cordula A" last="Jilg">Cordula A. Jilg</name></author><author><name sortKey="Leifert, Anja" sort="Leifert, Anja" uniqKey="Leifert A" first="Anja" last="Leifert">Anja Leifert</name></author><author><name sortKey="Schnell, Daniel" sort="Schnell, Daniel" uniqKey="Schnell D" first="Daniel" last="Schnell">Daniel Schnell</name></author><author><name sortKey="Kirste, Simon" sort="Kirste, Simon" uniqKey="Kirste S" first="Simon" last="Kirste">Simon Kirste</name></author><author><name sortKey="Volegova Neher, Natalia" sort="Volegova Neher, Natalia" uniqKey="Volegova Neher N" first="Natalia" last="Volegova-Neher">Natalia Volegova-Neher</name></author><author><name sortKey="Schlager, Daniel" sort="Schlager, Daniel" uniqKey="Schlager D" first="Daniel" last="Schlager">Daniel Schlager</name></author><author><name sortKey="Wieser, Gesche" sort="Wieser, Gesche" uniqKey="Wieser G" first="Gesche" last="Wieser">Gesche Wieser</name></author><author><name sortKey="Henne, Karl" sort="Henne, Karl" uniqKey="Henne K" first="Karl" last="Henne">Karl Henne</name></author><author><name sortKey="Schultze Seemann, Wolfgang" sort="Schultze Seemann, Wolfgang" uniqKey="Schultze Seemann W" first="Wolfgang" last="Schultze-Seemann">Wolfgang Schultze-Seemann</name></author><author><name sortKey="Grosu, Anca L" sort="Grosu, Anca L" uniqKey="Grosu A" first="Anca-L" last="Grosu">Anca-L Grosu</name></author><author><name sortKey="Rischke, Hans Christian" sort="Rischke, Hans Christian" uniqKey="Rischke H" first="Hans Christian" last="Rischke">Hans Christian Rischke</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Albert-Ludwigs University of Freiburg, Robert-Koch-Str, 3, 79106 Freiburg, Germany. hans.christian.rischke@uniklinik-freiburg.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Radiation Oncology, Albert-Ludwigs University of Freiburg, Robert-Koch-Str, 3, 79106 Freiburg</wicri:regionArea></affiliation></author></analytic><series><title level="j">Radiation oncology (London, England)</title><idno type="eISSN">1748-717X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Carbon Radioisotopes</term><term>Choline</term><term>Fluorine Radioisotopes</term><term>Humans</term><term>Lymph Node Excision (methods)</term><term>Lymphatic Metastasis (diagnostic imaging)</term><term>Male</term><term>Middle Aged</term><term>Multimodal Imaging</term><term>Neoplasm Recurrence, Local (diagnostic imaging)</term><term>Neoplasm Recurrence, Local (radiotherapy)</term><term>Neoplasm Recurrence, Local (surgery)</term><term>Positron-Emission Tomography</term><term>Prostatic Neoplasms (diagnostic imaging)</term><term>Prostatic Neoplasms (radiotherapy)</term><term>Prostatic Neoplasms (surgery)</term><term>Quality of Life</term><term>Radiopharmaceuticals</term><term>Radiotherapy, Adjuvant (methods)</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Choline</term><term>Humains</term><term>Imagerie multimodale</term><term>Lymphadénectomie ()</term><term>Mâle</term><term>Métastase lymphatique (imagerie diagnostique)</term><term>Qualité de vie</term><term>Radio-isotopes du carbone</term><term>Radio-isotopes du fluor</term><term>Radiopharmaceutiques</term><term>Radiothérapie adjuvante ()</term><term>Récidive tumorale locale ()</term><term>Récidive tumorale locale (imagerie diagnostique)</term><term>Récidive tumorale locale (radiothérapie)</term><term>Sujet âgé</term><term>Tomodensitométrie</term><term>Tomographie par émission de positons</term><term>Tumeurs de la prostate ()</term><term>Tumeurs de la prostate (imagerie diagnostique)</term><term>Tumeurs de la prostate (radiothérapie)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Carbon Radioisotopes</term><term>Choline</term><term>Fluorine Radioisotopes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lymphatic Metastasis</term><term>Neoplasm Recurrence, Local</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Métastase lymphatique</term><term>Récidive tumorale locale</term><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Lymph Node Excision</term><term>Radiotherapy, Adjuvant</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Neoplasm Recurrence, Local</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Récidive tumorale locale</term><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Neoplasm Recurrence, Local</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Multimodal Imaging</term><term>Positron-Emission Tomography</term><term>Quality of Life</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Choline</term><term>Humains</term><term>Imagerie multimodale</term><term>Lymphadénectomie</term><term>Mâle</term><term>Qualité de vie</term><term>Radio-isotopes du carbone</term><term>Radio-isotopes du fluor</term><term>Radiopharmaceutiques</term><term>Radiothérapie adjuvante</term><term>Récidive tumorale locale</term><term>Sujet âgé</term><term>Tomodensitométrie</term><term>Tomographie par émission de positons</term><term>Tumeurs de la prostate</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a previous study we demonstrated that, based on 11C/18 F-choline positron emission tomography-computerized-tomography as a diagnostic tool, salvage lymph node dissection (LND) plus adjuvant radiotherapy (ART) is feasible for treatment of pelvic/retroperitoneal nodal recurrence of prostate cancer (PCa). However, the toxicity of this combined treatment strategy has not been systematically investigated before. The aim of the current study was to evaluate the acute and late toxicity and quality of life of ART after LND in pelvic/retroperitoneal nodal recurrent PCa.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25112785</PMID><DateCreated><Year>2014</Year><Month>08</Month><Day>29</Day></DateCreated><DateCompleted><Year>2015</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1748-717X</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2014</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Radiation oncology (London, England)</Title><ISOAbbreviation>Radiat Oncol</ISOAbbreviation></Journal><ArticleTitle>Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.</ArticleTitle><Pagination><MedlinePgn>178</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1748-717X-9-178</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In a previous study we demonstrated that, based on 11C/18 F-choline positron emission tomography-computerized-tomography as a diagnostic tool, salvage lymph node dissection (LND) plus adjuvant radiotherapy (ART) is feasible for treatment of pelvic/retroperitoneal nodal recurrence of prostate cancer (PCa). However, the toxicity of this combined treatment strategy has not been systematically investigated before. The aim of the current study was to evaluate the acute and late toxicity and quality of life of ART after LND in pelvic/retroperitoneal nodal recurrent PCa.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">43 patients with nodal recurrent PCa were treated with 46 LND followed by ART (mean 49.6 Gy total dose) at the sites of nodal recurrence. Toxicity of ART was analysed by physically examination (31/43, 72.1%), by requesting 15 frequent items of adverse events from the Common-Terminology-Criteria for Adverse Events Version 4.0-catalogue and by review of medical records. QLQ-C30 (EORTC quality of life assessment) and PR25 (prostate cancer module) questionnaires were used to investigate quality of life. Toxicity was evaluated before starting of ART, during ART (acute toxicity), after ART (mean 2.3 months) and at end of follow up (mean 3.2 years after end of ART) reflecting late toxicity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">71.7% (33/46) of 46 ART were treatment of pelvic, 10.9% (5/46) of retroperitoneal only and 28.3% (13/46) of pelvic and retroperitoneal regions. Overall 52 symptoms representing toxicities were observed before ART, 107 during ART, 88 after end of ART and 52 at latest follow up. Leading toxicities during ART were diarrhoea (19%, 20/107), urinary incontinence (16%, 17/107) and fatigue (16%, 17/107). The spectrum of late toxicities was almost equal to those before beginning of ART. No grade 3 adverse events or chronic lymphedema at extremities were observed. We observed no clear correlation between localisation of treated regions, technique of ART and frequency or severity of toxicities. Mean quality of life at final evaluation was 74%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ART after extended LND in PCa relapse is justifiable with respect to adverse effects and toxicity. The side effects were circumscribed and well tolerated. The spectrum of adverse events at latest follow up was almost equal to those before start of ART.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jilg</LastName><ForeName>Cordula A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Leifert</LastName><ForeName>Anja</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schnell</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kirste</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Volegova-Neher</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Schlager</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wieser</LastName><ForeName>Gesche</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Henne</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Schultze-Seemann</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Grosu</LastName><ForeName>Anca-L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Rischke</LastName><ForeName>Hans Christian</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Albert-Ludwigs University of Freiburg, Robert-Koch-Str, 3, 79106 Freiburg, Germany. hans.christian.rischke@uniklinik-freiburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Radiat Oncol</MedlineTA><NlmUniqueID>101265111</NlmUniqueID><ISSNLinking>1748-717X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>N91BDP6H0X</RegistryNumber><NameOfSubstance UI="D002794">Choline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Urol. 2003 Feb;169(2):517-23</RefSource><PMID Version="1">12544300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Urol. 2014 Jul;192(1):103-10</RefSource><PMID Version="1">24518792</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Prostate Cancer. 2003 Jun;2(1):22-3</RefSource><PMID Version="1">15046679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiology. 2004 May;231(2):379-85</RefSource><PMID Version="1">15064390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 1993 Mar 3;85(5):365-76</RefSource><PMID Version="1">8433390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 1993;24 Suppl 2:72-6</RefSource><PMID Version="1">8262130</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1997 Mar 29;349(9056):906-10</RefSource><PMID Version="1">9093251</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1997 Aug 23;350(9077):535-40</RefSource><PMID Version="1">9284774</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Gynecol Cancer. 2006 May-Jun;16(3):1130-9</RefSource><PMID Version="1">16803496</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Jun 15;109(12):2607-14</RefSource><PMID Version="1">17474128</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55</RefSource><PMID Version="1">17531401</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2008 Nov;44(16):2418-24</RefSource><PMID Version="1">18774706</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2009 Feb;55(2):261-70</RefSource><PMID Version="1">18838212</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):29-35</RefSource><PMID Version="1">19467803</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2011 Nov;60(5):935-43</RefSource><PMID Version="1">21840116</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):889-97</RefSource><PMID Version="1">21277113</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2012 Dec;38(8):956-67</RefSource><PMID Version="1">22703831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Q J Nucl Med Mol Imaging. 2012 Oct;56(5):409-20</RefSource><PMID Version="1">23069920</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Strahlenther Onkol. 2012 Nov;188(11):982-9</RefSource><PMID Version="1">23053142</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Urol. 2012 Dec;188(6):2190-7</RefSource><PMID Version="1">23083862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Strahlenther Onkol. 2012 Dec;188(12):1096-101</RefSource><PMID Version="1">23128897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiat Oncol. 2012;7:185</RefSource><PMID Version="1">23114282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiat Oncol. 2013;8:276</RefSource><PMID Version="1">24279376</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Oncol (R Coll Radiol). 2014 Jan;26(1):10-7</RefSource><PMID Version="1">23992740</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiat Oncol. 2013;8:271</RefSource><PMID Version="1">24252686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Crit Rev Oncol Hematol. 2014 Apr;90(1):24-35</RefSource><PMID Version="1">24315428</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Aust N Z J Obstet Gynaecol. 2003 Apr;43(2):148-51</RefSource><PMID Version="1">14712972</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002794" MajorTopicYN="N">Choline</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064847" MajorTopicYN="N">Multimodal Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4251989</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>04</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>08</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25112785</ArticleId><ArticleId IdType="pii">1748-717X-9-178</ArticleId><ArticleId IdType="doi">10.1186/1748-717X-9-178</ArticleId><ArticleId IdType="pmc">PMC4251989</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001402 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001402 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25112785
|texte= Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25112785" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |